Pediatrix Medical Group (NYSE:MD) Earns Hold (C) Rating from Weiss Ratings

Pediatrix Medical Group (NYSE:MD)‘s stock had its “hold (c)” rating reissued by equities researchers at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

Several other research analysts also recently commented on MD. UBS Group boosted their price objective on shares of Pediatrix Medical Group from $16.00 to $16.50 and gave the company a “neutral” rating in a research report on Thursday, August 14th. Wall Street Zen raised shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 4th. Zacks Research lowered shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Truist Financial set a $17.00 price objective on shares of Pediatrix Medical Group in a report on Tuesday, October 14th. Finally, Leerink Partners upped their price objective on shares of Pediatrix Medical Group from $14.50 to $17.00 and gave the company a “market perform” rating in a report on Friday, September 5th. Two equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, Pediatrix Medical Group currently has an average rating of “Hold” and a consensus price target of $16.93.

Pediatrix Medical Group Price Performance

MD stock opened at $17.59 on Friday. The stock has a 50-day moving average price of $16.73 and a two-hundred day moving average price of $14.68. The stock has a market cap of $1.53 billion, a PE ratio of 13.63 and a beta of 1.26. The company has a current ratio of 1.80, a quick ratio of 1.80 and a debt-to-equity ratio of 0.70. Pediatrix Medical Group has a 1 year low of $11.84 and a 1 year high of $18.22.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.11. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The company had revenue of $468.84 million during the quarter, compared to analysts’ expectations of $464.37 million. During the same quarter last year, the company earned $0.34 EPS. Pediatrix Medical Group’s revenue for the quarter was down 7.1% compared to the same quarter last year. Equities analysts forecast that Pediatrix Medical Group will post 1.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Pediatrix Medical Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its position in Pediatrix Medical Group by 219.5% during the first quarter. GAMMA Investing LLC now owns 2,569 shares of the company’s stock worth $37,000 after buying an additional 1,765 shares in the last quarter. Marshall & Sullivan Inc. WA purchased a new stake in shares of Pediatrix Medical Group during the 2nd quarter valued at $41,000. Canada Pension Plan Investment Board purchased a new stake in shares of Pediatrix Medical Group during the 2nd quarter valued at $83,000. AlphaQuest LLC raised its position in shares of Pediatrix Medical Group by 16.0% during the 1st quarter. AlphaQuest LLC now owns 5,877 shares of the company’s stock valued at $85,000 after buying an additional 811 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Pediatrix Medical Group during the 2nd quarter valued at $99,000. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.